Table 4.
Baseline characteristics and relation with radiological response of the patients whose samples were analyzed by targeted NGS (n = 89)
| Total No. (%) | Responders No. (%) | Non-responders No. (%) | p | |
|---|---|---|---|---|
| Treatment | NS | |||
| Anastrozole (Arm A) | 41 (46.1) | 16 (42.1) | 25 (49.0) | |
| Fulvestrant (Arm B) | 48 (53.9) | 22 (57.9) | 26 (51.0) | |
| Age, mean (range), years | 71.9 (51–92) | 72.1 (51–87) | 72.0 (53–92) | NS |
| Age | NS | |||
| ≤ 70 years | 41 (46.1) | 14 (36.8) | 27 (52.9) | |
| > 70 years | 48 (53.9) | 24 (63.2) | 24 (41.1) | |
| ECOG PS | NS | |||
| 0 | 75 (84.3) | 33 (86.8) | 42 (82.4) | |
| 1 | 14 (15.7) | 5 (13.2) | 9 (17.6) | |
| Hormone replacement therapy | NS | |||
| Yes | 30 (33.7) | 15 (39.5) | 15 (29.4) | |
| No | 59 (66.3) | 24 (60.5) | 35(68.6) | |
| Tumor staging | NS | |||
| T2 | 74 (83.1) | 31 (81.6) | 43 (84.3) | |
| T3 | 11 (12.4) | 4 (10.5) | 7 (13.7) | |
| T4 | 4 (4.5) | 3 (7.9) | 1 (2.0) | |
| Node staging | NS | |||
| N0 | 66 (63.6) | 24 (63.2) | 42 (82.4) | |
| N1 | 21 (30.9) | 13 (34.2) | 8 (15.7) | |
| N2 | 2 (3.6) | 1 (2.6) | 1 (2.0) | |
| N3 | 0 (1.7) | 0 (0.0) | 0 (0.0) | |
| Elston-Ellis grade | NS | |||
| I | 20 (22.5) | 7 (18.4) | 13 (25.5) | |
| II | 57 (64.0) | 26 (68.4) | 31 (60.8) | |
| III | 9 (10.1) | 2 (5.3) | 7 (13.7) | |
| Unknown | 3 (3.4) | 3(7.9) | 0(0.0) | |
| Histological type | NS | |||
| Ductal | 55 (61.8) | 21 (55.3) | 34 (66.7) | |
| Lobular | 30 (33.7) | 14 (36.8) | 16 (31.4) | |
| Other | 4 (4.5) | 3 (7.9) | 1 (1.9) | |
| Allred score: ER | NS | |||
| 4–5 | 2 (2.2) | 2 (5.3) | 0 (0.0) | |
| 6 | 4 (4.5) | 3 (7.9) | 1 (2.0) | |
| 7 | 13 (14.6) | 5 (13.1) | 8 (15.7) | |
| 8 | 70 (78.7) | 28 (73.7) | 42 (82.3) | |
| Allred score: PR | NS | |||
| 0–5 | 38 (42.7) | 14 (36.8) | 24 (47.1) | |
| 6 | 14 (15.7) | 9 (23.7) | 5 (9.8) | |
| 7 | 20 (22.5) | 7 (18.4) | 13 (25.5) | |
| 8 | 17 (19.1) | 8 (21.1) | 9 (17.6) | |
| Ki-67 | NS | |||
| ≥ 20% | 25 (28.1) | 9 (23.7) | 16 (31.4) | |
| < 20% | 61 (68.5) | 28 (73.7) | 33 (64.7) | |
| ND | 3 (3.4) | 1 (2.6) | 2 (3.9) | |
ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, ND not determined, PR progesterone receptor, PS performance status, NS no significance